These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
270 related articles for article (PubMed ID: 20019121)
1. Can the response to iron therapy be predicted in anemic nondialysis patients with chronic kidney disease? Stancu S; Bârsan L; Stanciu A; Mircescu G Clin J Am Soc Nephrol; 2010 Mar; 5(3):409-16. PubMed ID: 20019121 [TBL] [Abstract][Full Text] [Related]
2. Oxidative stress markers in predicting response to treatment with ferric carboxymaltose in nondialysis chronic kidney disease patients. Prats M; Font R; García C; Muñoz-Cortés M; Cabré C; Jariod M; Romeu M; Giralt M; Martinez-Vea A Clin Nephrol; 2014 Jun; 81(6):419-26. PubMed ID: 24691014 [TBL] [Abstract][Full Text] [Related]
3. Iron isomaltoside 1000: a new intravenous iron for treating iron deficiency in chronic kidney disease. Wikström B; Bhandari S; Barany P; Kalra PA; Ladefoged S; Wilske J; Thomsen LL J Nephrol; 2011; 24(5):589-96. PubMed ID: 21240875 [TBL] [Abstract][Full Text] [Related]
4. A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD. Macdougall IC; Strauss WE; McLaughlin J; Li Z; Dellanna F; Hertel J Clin J Am Soc Nephrol; 2014 Apr; 9(4):705-12. PubMed ID: 24458078 [TBL] [Abstract][Full Text] [Related]
5. Comparison of Iron Dosing Strategies in Patients Undergoing Long-Term Hemodialysis: A Randomized Controlled Trial. Bielesz B; Lorenz M; Monteforte R; Prikoszovich T; Gabriel M; Wolzt M; Gleiss A; Hörl WH; Sunder-Plassmann G Clin J Am Soc Nephrol; 2021 Oct; 16(10):1512-1521. PubMed ID: 34470831 [TBL] [Abstract][Full Text] [Related]
6. Iron deficiency is a common cause of anemia in chronic kidney disease and can often be corrected with intravenous iron. Gotloib L; Silverberg D; Fudin R; Shostak A J Nephrol; 2006; 19(2):161-7. PubMed ID: 16736414 [TBL] [Abstract][Full Text] [Related]
7. Reticulocyte hemoglobin content predicts functional iron deficiency in hemodialysis patients receiving rHuEPO. Mittman N; Sreedhara R; Mushnick R; Chattopadhyay J; Zelmanovic D; Vaseghi M; Avram MM Am J Kidney Dis; 1997 Dec; 30(6):912-22. PubMed ID: 9398141 [TBL] [Abstract][Full Text] [Related]
9. Comparison of serum ferritin and transferrin saturation values associated with two i.v. iron formulations in hemodialysis patients. Nguyen TV Am J Health Syst Pharm; 2009 Jun; 66(12):1101-4. PubMed ID: 19498125 [TBL] [Abstract][Full Text] [Related]
10. Influence of intravenous iron therapy on novel markers of iron deficiency. Chinnappa S; Bhandari S Int J Artif Organs; 2010 May; 33(5):297-301. PubMed ID: 20593351 [TBL] [Abstract][Full Text] [Related]
11. Effect of Ferric Citrate versus Ferrous Sulfate on Iron and Phosphate Parameters in Patients with Iron Deficiency and CKD: A Randomized Trial. Womack R; Berru F; Panwar B; Gutiérrez OM Clin J Am Soc Nephrol; 2020 Sep; 15(9):1251-1258. PubMed ID: 32694162 [TBL] [Abstract][Full Text] [Related]
13. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. Coyne DW; Kapoian T; Suki W; Singh AK; Moran JE; Dahl NV; Rizkala AR; J Am Soc Nephrol; 2007 Mar; 18(3):975-84. PubMed ID: 17267740 [TBL] [Abstract][Full Text] [Related]
14. Maintenance of elevated versus physiological iron indices in non-anaemic patients with chronic kidney disease: a randomized controlled trial. McMahon LP; Kent AB; Kerr PG; Healy H; Irish AB; Cooper B; Kark A; Roger SD Nephrol Dial Transplant; 2010 Mar; 25(3):920-6. PubMed ID: 19906658 [TBL] [Abstract][Full Text] [Related]
15. Iron indices in chronic kidney disease in the National Health and Nutritional Examination Survey 1988-2004. Fishbane S; Pollack S; Feldman HI; Joffe MM Clin J Am Soc Nephrol; 2009 Jan; 4(1):57-61. PubMed ID: 18987297 [TBL] [Abstract][Full Text] [Related]
16. Serum Biomarkers of Iron Stores Are Associated with Increased Risk of All-Cause Mortality and Cardiovascular Events in Nondialysis CKD Patients, with or without Anemia. Guedes M; Muenz DG; Zee J; Bieber B; Stengel B; Massy ZA; Mansencal N; Wong MMY; Charytan DM; Reichel H; Waechter S; Pisoni RL; Robinson BM; Pecoits-Filho R; J Am Soc Nephrol; 2021 Aug; 32(8):2020-2030. PubMed ID: 34244326 [TBL] [Abstract][Full Text] [Related]
17. Bone marrow iron, iron indices, and the response to intravenous iron in patients with non-dialysis-dependent CKD. Stancu S; Stanciu A; Zugravu A; Bârsan L; Dumitru D; Lipan M; Mircescu G Am J Kidney Dis; 2010 Apr; 55(4):639-47. PubMed ID: 20079959 [TBL] [Abstract][Full Text] [Related]
18. Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. Provenzano R; Schiller B; Rao M; Coyne D; Brenner L; Pereira BJ Clin J Am Soc Nephrol; 2009 Feb; 4(2):386-93. PubMed ID: 19176796 [TBL] [Abstract][Full Text] [Related]
19. Hepcidin Response to Iron Therapy in Patients with Non-Dialysis Dependent CKD: An Analysis of the FIND-CKD Trial. Gaillard CA; Bock AH; Carrera F; Eckardt KU; Van Wyck DB; Bansal SS; Cronin M; Meier Y; Larroque S; Roger SD; Macdougall IC PLoS One; 2016; 11(6):e0157063. PubMed ID: 27276035 [TBL] [Abstract][Full Text] [Related]